Corcept Therapeutics
CORT
119.60
+0.03
+0.03%
Corcept Therapeutics
US · CORT
#1285 by market cap
Listed 1970
119.60
+0.03
+0.03%
Live - 5344 symbols - heartbeat 495s ago
· 2026-10-08 07:00
Pre-market
120.00
+0.33%
After-hours
119.60
0.00%
- Market cap
- 12.93B
- P/E (TTM)i
- 265.78
- P/Bi
- 18.32
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 93%
Reader sentiment
Are you bullish or bearish on CORT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 5 analysts
Buy
Avg price target
141.00 +17.9%
Price target rangecurrent 119.60
Low50.00
Avg141.00
High165.00
Buy 80%
Hold 0%
Sell 20%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-18 | H.C. Wainwright | -- | BUY | 165.00 |
| 2026-08-21 | Piper Sandler | -- | BUY | 165.00 |
| 2026-08-18 | Truist Financial | -- | BUY | 164.00 |
| 2026-08-13 | CCORF | -- | BUY | 161.00 |
| 2026-07-30 | CCORF | -- | BUY | 161.00 |
| 2026-07-30 | Piper Sandler | -- | BUY | 165.00 |
| 2026-07-30 | H.C. Wainwright | -- | BUY | 165.00 |
| 2026-07-29 | CCORF | -- | BUY | 161.00 |
| 2026-07-29 | Wolfe Research | -- | SELL | 50.00 |
| 2026-07-26 | Wolfe Research | -- | SELL | 50.00 |
| 2026-07-09 | CCORF | -- | BUY | 135.00 |
| 2026-06-02 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-06-01 | Piper Sandler | -- | BUY | 88.00 |
| 2026-06-01 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-05-28 | CCORF | -- | BUY | 135.00 |
| 2026-05-28 | H.C. Wainwright | -- | BUY | 95.00 |
| 2026-05-13 | UBS | -- | BUY | 72.00 |
| 2026-05-04 | CCORF | -- | BUY | 110.00 |
| 2026-05-04 | H.C. Wainwright | -- | BUY | 75.00 |
| 2026-05-01 | Piper Sandler | -- | BUY | 88.00 |
| 2026-04-28 | CCORF | -- | BUY | 110.00 |
| 2026-04-08 | CCORF | -- | BUY | 110.00 |
| 2026-03-30 | CCORF | -- | BUY | 110.00 |
| 2026-03-30 | Piper Sandler | -- | BUY | 73.00 |
| 2026-03-26 | CCORF | -- | BUY | 110.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 1
■ Upgrades■ Downgrades
- 2 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Wolfe Research moved from Hold to Sell on 2026-07-26.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-07-26 | Wolfe Research | HOLD → SELL | 50.00 |
| 2026-05-13 | UBS | HOLD → BUY | 72.00 |
| 2026-03-26 | Wolfe Research | SELL → HOLD | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-29 | After close | ±11.98% | +27.29% (beat) |
| 2026/Q1 | 2026-04-30 | After close | ±8.03% | +10.53% (beat) |
| 2025/Q4 | 2026-02-24 | After close | ±10.55% | -0.71% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±12.65% | +7.81% (in line) |
| 2025/Q2 | 2025-07-31 | After close | ±11.59% | +2.72% (in line) |
| 2025/Q1 | 2025-05-05 | After close | ±12.10% | -4.33% (in line) |
| 2024/Q4 | 2025-02-26 | After close | ±23.17% | -5.55% (in line) |
| 2024/Q3 | 2024-10-30 | After close | ±18.92% | +4.44% (in line) |
| 2024/Q2 | 2024-07-29 | After close | ±15.02% | -1.12% (in line) |
| 2024/Q1 | 2024-05-01 | After close | ±13.10% | +4.94% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±17.81% | -7.15% (in line) |
| 2023/Q3 | 2023-11-01 | After close | ±12.32% | -9.97% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:10 · For reference only, not investment advice and not tailored to your situation.